Clinical trials
catalyst calendar across sponsors →Studies where HYPR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 6 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, MARSHALL WACE, LLP, TWO SIGMA INVESTMENTS, LP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Squarepoint Ops LLC, +1 more) · FINRA short interest 3.8 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging SystemsNCT07296263Radiologist-rated lesion border delineation on post-contrast portable MRIOpen-label · Other | Not applicable | Enrolling by invitation | Device: Portable MRI (pMRI) · Drug: Gadolinium-Based Contrast Agent (GBCA) | Intra-axial Tumors, Extra-axial Tumors, Infection/Inflammatory Lesions | 85 | 2026-07-31 | 2026-07-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19